Interpace Biosciences (OTCMKTS:IDXG) Stock Passes Above 200-Day Moving Average – Here’s Why

Interpace Biosciences, Inc. (OTCMKTS:IDXG)’s share price passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $1.59 and traded as high as $1.76. Interpace Biosciences shares last traded at $1.76, with a volume of 3,012 shares trading hands.

Interpace Biosciences Price Performance

The business has a fifty day moving average price of $1.91 and a two-hundred day moving average price of $1.59. The firm has a market capitalization of $7.80 million, a price-to-earnings ratio of -35.20 and a beta of 0.59.

Interpace Biosciences (OTCMKTS:IDXG) last posted its earnings results on Tuesday, May 12th. The business services provider reported $0.03 EPS for the quarter. The firm had revenue of $9.03 million for the quarter. Interpace Biosciences had a return on equity of 219.07% and a net margin of 65.25%.

Interpace Biosciences Company Profile

Interpace Biosciences, Inc provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer.